Log in

NASDAQ:OTIC - Otonomy Stock Price, Forecast & News

$2.50
-0.02 (-0.79 %)
(As of 12/8/2019 05:41 AM ET)
Today's Range
$2.49
Now: $2.50
$2.58
50-Day Range
$2.18
MA: $2.39
$2.60
52-Week Range
$1.50
Now: $2.50
$3.15
Volume65,089 shs
Average Volume77,821 shs
Market Capitalization$76.88 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53
Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OTIC
CUSIPN/A
Phone619-323-2200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$750,000.00
Book Value$2.60 per share

Profitability

Net Income$-50,370,000.00
Net Margins-6,516.78%

Miscellaneous

Employees49
Market Cap$76.88 million
Next Earnings Date3/2/2020 (Estimated)
OptionableOptionable

Receive OTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for OTIC and its competitors with MarketBeat's FREE daily newsletter.


Otonomy (NASDAQ:OTIC) Frequently Asked Questions

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

How were Otonomy's earnings last quarter?

Otonomy Inc (NASDAQ:OTIC) announced its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.12. The biopharmaceutical company earned $0.13 million during the quarter, compared to the consensus estimate of $0.31 million. Otonomy had a negative net margin of 6,516.78% and a negative return on equity of 72.06%. View Otonomy's Earnings History.

When is Otonomy's next earnings date?

Otonomy is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Otonomy.

What price target have analysts set for OTIC?

3 equities research analysts have issued 12-month price objectives for Otonomy's shares. Their forecasts range from $5.00 to $8.00. On average, they expect Otonomy's share price to reach $6.50 in the next twelve months. This suggests a possible upside of 160.0% from the stock's current price. View Analyst Price Targets for Otonomy.

What is the consensus analysts' recommendation for Otonomy?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Otonomy.

What are Wall Street analysts saying about Otonomy stock?

Here are some recent quotes from research analysts about Otonomy stock:
  • 1. According to Zacks Investment Research, "Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company's product candidates under development includes AuriPro to treat pediatric patients with middle ear effusion; and OTO-104 for the treatment of patients with Ménière's disease. Otonomy, Inc. is headquartered in San Diego, California. " (11/9/2019)
  • 2. HC Wainwright analysts commented, "Our $8 12-month target is based on a 60% probability of success adjusted DCF. We only include in our model—assuming 2022 launch and over $300M peak sales—and do not include any contribution from the early-stage pipeline. Our DCF reflects a 12% WACC discount rate and 1% terminal growth beyond 2028, which we think is appropriate assuming IP into the 2030s, and a likely high generic bioequivalence bar for locally acting therapy, requiring a head-to-head clinical trial." (8/29/2019)

Has Otonomy been receiving favorable news coverage?

Media headlines about OTIC stock have trended negative this week, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Otonomy earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Otonomy.

Are investors shorting Otonomy?

Otonomy saw a drop in short interest in the month of November. As of November 15th, there was short interest totalling 113,700 shares, a drop of 6.4% from the October 31st total of 121,500 shares. Based on an average daily trading volume, of 56,900 shares, the days-to-cover ratio is presently 2.0 days. Approximately 0.5% of the company's stock are sold short. View Otonomy's Current Options Chain.

Who are some of Otonomy's key competitors?

What other stocks do shareholders of Otonomy own?

Who are Otonomy's key executives?

Otonomy's management team includes the folowing people:
  • Dr. Jay B. Lichter, Co-Founder & Chairman (Age 57)
  • Dr. David Allen Weber, Pres, CEO & Director (Age 59)
  • Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 57)
  • Mr. Robert Michael Savel II, Chief Technical Officer (Age 51)
  • Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel

Who are Otonomy's major shareholders?

Otonomy's stock is owned by a number of of retail and institutional investors. Top institutional investors include Man Group plc (0.36%). View Institutional Ownership Trends for Otonomy.

Which major investors are selling Otonomy stock?

OTIC stock was sold by a variety of institutional investors in the last quarter, including Man Group plc. View Insider Buying and Selling for Otonomy.

How do I buy shares of Otonomy?

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $2.50.

How big of a company is Otonomy?

Otonomy has a market capitalization of $76.88 million and generates $750,000.00 in revenue each year. The biopharmaceutical company earns $-50,370,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Otonomy employs 49 workers across the globe.View Additional Information About Otonomy.

What is Otonomy's official website?

The official website for Otonomy is http://www.otonomy.com/.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]


MarketBeat Community Rating for Otonomy (NASDAQ OTIC)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  282 (Vote Outperform)
Underperform Votes:  269 (Vote Underperform)
Total Votes:  551
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: What is operating income?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel